https://orcid.org/0000-0001-7799-4291
Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Adam Reich, Catherine Reed, Christopher Schuster, Camille Robert, Tamas Treuer & Ennio Lubrano. (2023) Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021. Journal of Dermatological Treatment 34:1.
Read now
Read now
Giacomo Caldarola, A Chiricozzi, M Megna, P Dapavo, A Giunta, M Burlando, P Malagoli, V Dini, M Mariani, G Fabbrocini, P Quaglino, L Bianchi, A Parodi, K Peris & C De Simone. (2023) Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study. Expert Opinion on Biological Therapy 23:4, pages 365-370.
Read now
Read now
Caterina Lanna, Sara Lambiase, Ruslana Gaeta Shumak, Cristiana Borselli, Terenzio Cosio, Annunziata Dattola, Luca Bianchi & Elena Campione. (2022) Why targeted therapeutics have provided benefit in psoriasis: looking at IL-17 biology. Expert Review of Clinical Pharmacology 15:10, pages 1209-1224.
Read now
Read now
Pim Sermsaksasithorn, Chanidapa Wongtada, Varin Chaaim, Yuda Chongpison & Pravit Asawanonda. (2022) On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study. Journal of Dermatological Treatment 33:7, pages 2963-2974.
Read now
Read now
Articles from other publishers (7)
Estela García-Martín, RM Romero-Jiménez, Ofelia Baniandrés-Rodríguez, Vicente Escudero-Vilaplana, Juana Benedí-González, Paloma Morales de los Ríos Luna, Ana Herranz-Alonso & María Sanjurjo-Sáez. (2023) Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors. European Journal of Hospital Pharmacy, pages ejhpharm-2022-003594.
Crossref
Crossref
Lisa Schots, Rani Soenen, Brigitte Blanquart, Debby Thomas & Jo Lambert. (2023)
Blocking interleukin‐17 in psoriasis: Real‐world experience from the
PsoPlus
cohort
. Journal of the European Academy of Dermatology and Venereology 37:4, pages 698-710.
Crossref
Crossref
Pravit Asawanonda, Bensachee Pattamadilok, Leena Chularojanamontri, Mati Chuamanochan, Charoen Choonhakarn, Panlop Chakkavittumrong, Naruemon Sangob & Natta Rajatanavin. (2022) Real‐world experience of secukinumab in moderate to severe psoriasis patients in Thailand: Characteristics, effectiveness, and safety. Dermatologic Therapy 35:12.
Crossref
Crossref
Xi‐Bei Chen, Yu‐Xin Zheng, Li‐Ran Ye, Xue‐Yan Chen & Xiao‐Yong Man. (2022) Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single‐center, uncontrolled, prospective study in 36 weeks. Dermatologic Therapy 35:12.
Crossref
Crossref
Matteo Megna, Luca Potestio, Elisa Camela, Gabriella Fabbrocini & Angelo Ruggiero. (2022) Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting. Dermatologic Therapy 35:9.
Crossref
Crossref
Marko Barešić, Ljiljana Smiljanić Tomičević, Branimir Anić & Miroslav Mayer. (2022) Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review. Rheumatology International 42:2, pages 365-370.
Crossref
Crossref
Frank Kolbinger, Franco Di Padova, Atul Deodhar, Jason E. Hawkes, Christine Huppertz, Torsten Kuiper, Iain B. McInnes, Christopher T. Ritchlin, David Rosmarin, Georg Schett, José M. Carballido, Peter Häusermann, Claudio Calonder, Beate Vogel, Jean-Michel Rondeau & Gerard Bruin. (2022) Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety. Pharmacology & Therapeutics 229, pages 107925.
Crossref
Crossref